{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T14:02:07Z","timestamp":1775311327691,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.msard.2023.104800","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T19:54:05Z","timestamp":1685994845000},"page":"104800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Current and future trends in multiple sclerosis management: Near East perspective"],"prefix":"10.1016","volume":"76","author":[{"given":"Anmar","family":"Hatem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil K","family":"El Ayoubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed","family":"Habahbeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Ghanim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad","family":"Al-Naqshbandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abed","family":"Raki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoda","family":"Joudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.msard.2023.104800_bib0001","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s10072-017-3080-9","article-title":"Multiple sclerosis and environmental risk factors: a case-control study in Iran","volume":"38","author":"Abbasi","year":"2017","journal-title":"Neurol. Sci.: Off. J. Italian Neurol. Soc. Italian Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.msard.2023.104800_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103686","article-title":"Epidemiology of multiple sclerosis in West bank of Palestine","volume":"59","author":"Abuawad","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.104800_bib0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12883-021-02281-x","article-title":"Multiple sclerosis projection in Tehran, Iran using Bayesian structural time series","volume":"21","author":"Amini","year":"2021","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104800_bib0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","article-title":"The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: global Adherence Project: adherence to DMTs in MS","volume":"18","author":"Devonshire","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.104800_bib0005","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ene.13236","article-title":"Survey of diagnostic and treatment practices for multiple sclerosis in Europe","volume":"24","author":"Fern\u00e1ndez","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.104800_bib0006","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40120-018-0112-1","article-title":"European and American guidelines for multiple sclerosis treatment","volume":"7","author":"Ghezzi","year":"2018","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.msard.2023.104800_bib0007","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40120-015-0033-1","article-title":"Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience","volume":"4","author":"Gold","year":"2015","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.msard.2023.104800_bib0008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/01616412.2021.1952511","article-title":"Epidemiology of multiple sclerosis in Iraq: retrospective review of 4355 cases and literature review","volume":"44","author":"Hassoun","year":"2022","journal-title":"Neurol. Res."},{"issue":"3","key":"10.1016\/j.msard.2023.104800_bib0009","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2023.104800_bib0010","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2023.104800_bib0011","doi-asserted-by":"crossref","first-page":"e1114","DOI":"10.1212\/NXI.0000000000001114","article-title":"Interim analysis of pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry","volume":"9","author":"Hellwig","year":"2022","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2023.104800_bib0012","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000431042","article-title":"Multiple sclerosis epidemiology in Middle East and North Africa: a systematic review and meta-analysis","volume":"44","author":"Heydarpour","year":"2015","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.msard.2023.104800_bib0013","doi-asserted-by":"crossref","unstructured":"Heydarpour, P., Mohammad, K., Yekaninejad, M.S., Elhami, S.R., Khoshkish, S., & Sahraian, M.A. (2014). Multiple sclerosis in Tehran, Iran: a join point trend analysis. Multiple Sclerosis (Houndmills, Basingstoke, England), 20(4), 512. https:\/\/doi.org\/10.1177\/1352458513494496.","DOI":"10.1177\/1352458513494496"},{"issue":"9805","key":"10.1016\/j.msard.2023.104800_bib0014","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.msard.2023.104800_bib0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Multiple Scler. J."},{"issue":"3","key":"10.1016\/j.msard.2023.104800_bib0016","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2023.104800_bib0017","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s40263-021-00833-w","article-title":"Utilization of multiple sclerosis therapies in the Middle East over a decade: 2009\u20132018","volume":"35","author":"Moradi","year":"2021","journal-title":"CNS Drugs"},{"issue":"17","key":"10.1016\/j.msard.2023.104800_bib0018","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2023.104800_bib0020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/GCO.0000000000000731","article-title":"Pregnancy and multiple sclerosis: an update","volume":"33","author":"Varyt\u0117","year":"2021","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.msard.2023.104800_bib0021","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Wallin","year":"2019","journal-title":"Lancet Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2023.104800_bib0022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jns.2008.02.009","article-title":"Clinical characteristics of multiple sclerosis in Lebanon","volume":"270","author":"Yamout","year":"2008","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2023.104800_bib0023","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/00207450903464587","article-title":"Prognostic factors of multiple sclerosis in Lebanon","volume":"120","author":"Yamout","year":"2010","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.msard.2023.104800_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101459","article-title":"Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines","volume":"37","author":"Yamout","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.104800_bib0025","article-title":"Treatment of multiple sclerosis in special populations: the case of refugees","volume":"6","author":"Zeineddine","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:08:32Z","timestamp":1761901712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823003024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":24,"alternative-id":["S2211034823003024"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104800","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future trends in multiple sclerosis management: Near East perspective","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104800"}}